论文部分内容阅读
目的探讨阿德福韦酯对慢性乙型肝炎的疗效。方法慢性乙型肝炎患者50例分为两组:A组22例,口服阿德福韦酯10mg/d;B组28例,采用常规保肝降酶治疗。于治疗前及治疗48周后检查肝功能及血清HBV DNA,并在B超引导下行肝组织穿刺术,行炎症活动度分级及纤维化程度分期的评分。结果治疗后,A组ALT恢复正常率高于B组(86.4%vs.53.6%)(P<0.05),A组HBV DNA转阴率高于B组(63.6%vs.7.1%)(P<0.01)。A组炎症分级改善率高于B组(68.2%vs.35.7)(P<0.05),A组纤维化分期改善高于B组(50.0%vs.21.4%)(P<0.05)。结论阿德福韦酯能明显改善慢性乙型肝炎患者肝脏炎症及纤维化水平。
Objective To investigate the effect of adefovir dipivoxil on chronic hepatitis B Methods 50 patients with chronic hepatitis B were divided into two groups: A group of 22 cases, oral adefovir dipivoxil 10mg / d; B group of 28 cases, using conventional liver protection enzyme treatment. Liver function and serum HBV DNA were examined before treatment and after 48 weeks of treatment. Liver biopsy was performed under the guidance of B ultrasound, and the grading of inflammation activity and fibrosis stage were also scored. Results After treatment, the recovery rate of ALT in group A was significantly higher than that in group B (86.4% vs.53.6%, P <0.05). The negative rate of HBV DNA in group A was significantly higher than that in group B (63.6% vs.7.1%, P < 0.01). The improvement rate of inflammation grade in group A was higher than that in group B (68.2% vs.35.7) (P <0.05). The improvement of fibrosis stage in group A was higher than that in group B (50.0% vs.21.4%, P <0.05). Conclusion Adefovir dipivoxil can significantly improve liver inflammation and fibrosis in patients with chronic hepatitis B.